RhumbLine Advisers
LXEO icon

RhumbLine Advisers’s Lexeo Therapeutics LXEO Stock Holding History

RhumbLine Advisers’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$372K Buy
79,809
+7,727
+11% +$41.8K ﹤0.01% 2941
2026
Q1 		$414K Buy
72,082
+2,713
+4% +$19.2K ﹤0.01% 2725
2025
Q4 		$689K Buy
69,369
+37,605
+118% +$343K ﹤0.01% 2453
2025
Q3 		$211K Sell
31,764
-226
-0.7% -$1.09K ﹤0.01% 3193
2025
Q2 		$129K Buy
31,990
+1,798
+6% +$5.91K ﹤0.01% 3441
2025
Q1 		$105K Buy
30,192
+4,995
+20% +$22.1K ﹤0.01% 3375
2024
Q4 		$166K Buy
25,197
+4,127
+20% +$32.5K ﹤0.01% 3293
2024
Q3 		$190K Buy
21,070
+7,713
+58% +$92K ﹤0.01% 3264
2024
Q2 		$214K Buy
13,357
+3,627
+37% +$52.7K ﹤0.01% 3192
2024
Q1 		$153K Buy
+9,730
New +$152K ﹤0.01% 3294

Other funds holding LXEO

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

RhumbLine Advisers's LXEO Position: Q2 2026 in Review

RhumbLine Advisers increased its Lexeo Therapeutics (LXEO) stake by 11% in Q2 2026, buying an estimated $41.8K and bringing the position to 79,809 shares worth $372K. The position accounts for ﹤0.01% of the portfolio, ranked #2941.

RhumbLine Advisers first reported a position in LXEO in Q1 2024 and has held it in 10 quarters since. The position peaked at $689K in Q4 2025. 141 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

  • RhumbLine Advisers held 79,809 shares of Lexeo Therapeutics worth $372K as of Q2 2026.
  • RhumbLine Advisers bought 7,727 Lexeo Therapeutics shares in Q2 2026, an estimated $41.8K.
  • Lexeo Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #2941 holding.
  • RhumbLine Advisers first reported a position in Lexeo Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • RhumbLine Advisers's Lexeo Therapeutics position peaked at $689K in Q4 2025.
  • 141 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.